Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions

Abstract

Recently, mepolizumab, an interleukin (IL)-5 inhibitor, has been indicated for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) refractory to standard therapies. However, no reports have compared the efficacy of mepolizumab according to symptoms and organ lesions. Herein, we report two cases in which mepolizumab was highly effective in the management of EGPA with lung lesions and otitis media refractory to treatment with multiple immunosuppressive agents. These two cases suggest that mepolizumab is effective in treating pulmonary and ear lesions in EGPA.

Keywords:

• Eosinophilic granulomatosis with polyangiitis
• ANCA-associated vasculitis
• lung lesions
• otitis media with ANCA-associated vasculitis
• mepolizumab

Acknowledgements

We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Patient consent

We obtained the patients’ written consent prior for this publication prior to submitting this article.

Ethical approval

Not applicable.

Conflict of interest

None.